Placental Pathology and Neonatal Outcomes in Pregnancies of Perinatally vs. Nonperinatally HIV-Infected Women
Background. Perinatally HIV-infected (PHIV) women are reaching childbearing age, but little is known about the impact of long-term exposure to HIV and antiretroviral therapy on pregnancy outcomes of PHIV women, including the impact on neonatal health and placental pathology.
Methods. We performed a retrospective cohort analysis over a 10-year period (2007) (2008) (2009) (2010) (2011) (2012) (2013) (2014) (2015) (2016) (2017) of PHIV women, matched by age and date of delivery in 1:2 ratio, to behaviorally HIV-infected women (BHIV). The primary maternal outcome variable included virologic suppression (viral load ≤ 400 copies/mL) at delivery. Secondary outcome variables included hospital length of stay (LOS), mode of delivery, infectious (chorioamnionitis, funisitis) and vascular (vasculitis) placental complications based on histopathological analysis of placental specimen (composite variable). The primary neonatal outcome was preterm birth (<37 weeks); secondary neonatal outcomes included APGAR scores and infant HIV status. Primary and secondary maternal and neonatal outcomes were compared between PHIV and BHIV women. Logistic regression models measured the association between primary maternal and neonatal outcomes and perinatal status, adjusting for age and race.
Results. A total of 60 deliveries were evaluated during the study period (20 from women with PHIV and 40 from BHIV). Women with PHIV were significantly younger (20 vs. 29, P < 0.05) and less likely to be suppressed at delivery (55% vs. 90%, P < 0.05) compared with women with BHIV. A total of 19 women experienced placental pathologies but no differences were found by perinatal status (31% vs. 36%, P = 0.7, among PHIV and BHIV, respectively). Other than viral suppression, there were no significant differences among maternal and neonatal outcomes of interest by mode of HIV acquisition. In the multivariable regression, women with PHIV were significantly less likely to be suppressed after adjusting for age and race (AOR 0.07, 95% CI 0.01-0.80). There was no significant difference for preterm birth.
Conclusion. Women with PHIV were significantly less likely to be suppressed at delivery but did not experience other complications at birth. Neonatal outcomes were similar among women with PHIV and BHIV.
Disclosures. All authors: No reported disclosures. In the past 2 years, the North Florida region had 31% of the total number of HIV-infected infants. Eight of 12 mothers transmitting infection were known to be HIV infected and were prescribed antiretroviral (ARV) therapy with noncompliance documented in all 8. Two were teenagers; four received no prenatal care and insurance problems were reported in 3 as reasons for ARV noncompliance. Mental illness and/or substance abuse was documented in 6. Three were presumed infected during the third trimester-two tested negative in the first trimester, one was retested early in the third trimester and one was tested only at delivery due to lack of prenatal care.
Increase in Perinatal HIV Infection in North Florida: Missed Opportunities to Prevent Maternal-to-Child Transmission in Rural Areas
Conclusion. Improved access to prenatal case management and access to mental health and substance abuse services are seriously needed in rural areas. Improving pregnancy compliance with ARV therapy is crucial in preventing vertical transmission. The number of perinatal coordinators needs to be significantly increased to support compliance and provides services. HIV testing in the first and third trimesters should become routine and testing of all (but especially high-risk women such as teenagers and those with mental illness or substance abuse) should be strongly considered at the time of delivery.
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